Endovascular Therapy Is Effective and Safe for Patients With Severe Ischemic Stroke

Joseph P. Broderick*, Olvert A. Berkhemer, Yuko Y. Palesch, Diederik W. J. Dippel, Lydia D. Foster, Yvo B. W. E. M. Roos, Aad van der Lugt, Thomas A. Tomsick, Charles B. L. M. Majoie, Wim H. van Zwam, Andrew M. Demchuk, Robert J. van Oostenbrugge, Pooja Khatri, Hester F. Lingsma, Michael D. Hill, Bob Roozenbeek, Edward C. Jauch, Tudor G. Jovin, Bernard Yan, Ruediger von KummerCarlos A. Molina, Mayank Goyal, Wouter J. Schonewille, Mikael Mazighi, Stefan T. Engelter, Craig S. Anderson, Judith Spilker, Janice Carrozzella, Karla J. Ryckborst, L. Scott Janis, Kit N. Simpson

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

31 Citations (Web of Science)

Abstract

Background and Purpose-We assessed the effect of endovascular treatment in acute ischemic stroke patients with severe neurological deficit (National Institutes of Health Stroke Scale score, >= 20) after a prespecified analysis plan. Methods-The pooled analysis of the Interventional Management of Stroke III (IMS III) and Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands (MR CLEAN) trials included participants with an National Institutes of Health Stroke Scale score of >= 20 before intravenous tissue-type plasminogen activator (tPA) treatment (IMS III) or randomization (MR CLEAN) who were treated with intravenous tPA
Original languageEnglish
Pages (from-to)3416-3422
JournalStroke
Volume46
Issue number12
DOIs
Publication statusPublished - Dec 2015

Keywords

  • clinical trial
  • endovascular procedures
  • stroke
  • tissue-type plasminogen activator

Cite this